Last reviewed · How we verify
BIMERVAX
BIMERVAX is designed to stimulate an immune response against specific pathogens or antigens.
BIMERVAX is designed to stimulate an immune response against specific pathogens or antigens. Used for Prevention of diseases caused by specific pathogens (indication details pending clinical trials).
At a glance
| Generic name | BIMERVAX |
|---|---|
| Sponsor | Hipra Scientific, S.L.U |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 2 |
Mechanism of action
It works by introducing an antigenic component that mimics the pathogen, thereby activating the immune system to produce antibodies and memory cells, which can provide protection against future infections.
Approved indications
- Prevention of diseases caused by specific pathogens (indication details pending clinical trials)
Common side effects
- Injection site reactions
- Fever
- Fatigue
Key clinical trials
- Open-label, Multi-centre, Non-Inferiority Study of Safety and Immunogenicity of BIMERVAX for the Prevention of COVID-19 in Adolescents From 12 Years to Less Than 18 Years of Age. (PHASE2)
- A Phase II Trial to Evaluate the Safety and Immunogenicity of BIMERVAX® When Coadministered With Seasonal Influenza Vaccine (SIIV) in Adults Older Than 65 Years of Age Fully Vaccinated Against COVID-19 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BIMERVAX CI brief — competitive landscape report
- BIMERVAX updates RSS · CI watch RSS
- Hipra Scientific, S.L.U portfolio CI